Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib

Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotini...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jun-Li, Ren, Xiao-Cang, Lin, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037325/
https://www.ncbi.nlm.nih.gov/pubmed/24876785
http://dx.doi.org/10.2147/OTT.S49233
_version_ 1782318239681871872
author Liang, Jun-Li
Ren, Xiao-Cang
Lin, Qiang
author_facet Liang, Jun-Li
Ren, Xiao-Cang
Lin, Qiang
author_sort Liang, Jun-Li
collection PubMed
description Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. Since being launched August 2011 in the People’s Republic of China, icotinib has been widely used in clinics, and has become an important treatment option for Chinese patients with advanced NSCLC. The present study presents the Phase I, II, and III clinical trials of icotinib and discusses current clinical applications in the People’s Republic of China and future research directions.
format Online
Article
Text
id pubmed-4037325
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40373252014-05-29 Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib Liang, Jun-Li Ren, Xiao-Cang Lin, Qiang Onco Targets Ther Review Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. Since being launched August 2011 in the People’s Republic of China, icotinib has been widely used in clinics, and has become an important treatment option for Chinese patients with advanced NSCLC. The present study presents the Phase I, II, and III clinical trials of icotinib and discusses current clinical applications in the People’s Republic of China and future research directions. Dove Medical Press 2014-05-16 /pmc/articles/PMC4037325/ /pubmed/24876785 http://dx.doi.org/10.2147/OTT.S49233 Text en © 2014 Liang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Liang, Jun-Li
Ren, Xiao-Cang
Lin, Qiang
Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
title Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
title_full Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
title_fullStr Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
title_full_unstemmed Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
title_short Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
title_sort treating advanced non-small-cell lung cancer in chinese patients: focus on icotinib
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037325/
https://www.ncbi.nlm.nih.gov/pubmed/24876785
http://dx.doi.org/10.2147/OTT.S49233
work_keys_str_mv AT liangjunli treatingadvancednonsmallcelllungcancerinchinesepatientsfocusonicotinib
AT renxiaocang treatingadvancednonsmallcelllungcancerinchinesepatientsfocusonicotinib
AT linqiang treatingadvancednonsmallcelllungcancerinchinesepatientsfocusonicotinib

Ejemplares similares